pharmaceuticals

$5

Expired Patents Take a Bite out of Eli Lilly Results

Eli Lilly & Co. (NYSE: LLY) reported first-quarter 2014 results before markets opened Thursday. The pharmaceutical giant posted adjusted diluted earnings per share (EPS) of $0.68 on revenues of $4.68 ...
Read Full Story »
biotech

Companies Betting on the Next 10 Blockbuster Drugs

The biotech sector has seen its valuations hit hard in many cases in 2014, but many investors remain excited about the future wave of big biotech drugs -- and big ...
Read Full Story »
DNA

UBS Top Stocks to Buy Working for Cancer Cures

Cancer is the leading cause of death globally, and a disease that touches almost every person in our nation one way or another. In a new research report, the Healthcare ...
Read Full Story »
cannabis

GW Pharma Dual Cannabinoid Endorsement: Morgan Stanley and Jim Cramer

GW Pharmaceuticals PLC (NASDAQ: GWPH) is far from your typical pharma or biotech stock. It is also far from your typical legalized marijuana or medical marijuana stock. That being said, ...
Read Full Story »
Pills

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. The biggest is the possible deal between activist hedge fund manager Bill Ackman's Pershing Square, Valeant ...
Read Full Story »
biotech

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

It is not that common that you hear about mergers in the $50 billion range. But what about when you hear of mergers in the $80 billion or $100 billion ...
Read Full Story »
DNA

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Since March 4, the biotech index is off a massive 19%. There has been plenty of Wall Street speculation on why the sell-off was so violent, but at the end ...
Read Full Story »
Johnson & Johnson Logo

Johnson & Johnson Earnings Point to New 52-Week High

Johnson & Johnson (NYSE: JNJ) reported first-quarter results before markets opened Tuesday. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.54 on revenue of $18.1 ...
Read Full Story »
buy sell

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Gilead Sciences Inc. (NASDAQ: GILD) may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance above and ...
Read Full Story »
biotech

Why Questcor Buyout Will Not Deter Short Sellers

The $5.6 billion acquisition of Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) by specialty drugmaker Mallinckrodt PLC (NYSE: MNK) started the week off with a big bang. Shares of Questcor originally leaped ...
Read Full Story »
Food and Drug Administration logo

FDA Keeps Driving Up Future Cost of Inhalable Insulin

MannKind Corp. (NASDAQ: MNKD) is suffering another setback from the U.S. Food & Drug Administration. While the FDA has been far from a friend to MannKind over the past few ...
Read Full Story »
research

Credit Suisse Says Grit Your Teeth and Buy Biotech

For the second time since late February, a huge run on the momentum, and specifically biotech, names hit the market last week. Again, the biotech benchmark took a huge 4% ...
Read Full Story »
DNA

Pancreatic Cancer Trial Enrollment Halt Damages Halozyme

Halozyme Therapeutics Inc. (NASDAQ: HALO) will need some therapeutics of its own, as are its shareholders. Its shares got pounded Friday morning on news of a temporary halt of its ...
Read Full Story »
biotech

Amgen Faces Cool Reception Over GSK Pact Termination

Amgen Inc. (NASDAQ: AMGN) submitted an SEC Filing showing that, as of April 1, its Amgen Manufacturing Ltd. subsidiary and GlaxoSmithKline PLC (NYSE: GSK), via Glaxo Group Ltd., have terminated ...
Read Full Story »
76764023

Can MannKind Shares Double Again on FDA Approval? (Final)

MannKind Corp. (NASDAQ: MNKD) has a serious victory within its grasp. The company has struggled to get its Afrezza inhalable insulin to market for years, and that dream now seems ...
Read Full Story »